Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Profile Name | FLT3 positive |
Gene Variant Detail | |
Relevant Treatment Approaches |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
FLT3 positive | acute myeloid leukemia | predicted - sensitive | AGS62P1 | Preclinical - Patient cell culture | Actionable | In a preclinical study, AGS62P1 inhibited growth of FLT3-positive acute myeloid leukemia cell lines in culture, and led to tumor growth inhibition and regression in patient-derived xenograft (PDX) models (Blood 2015 126(23):3806). | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02846376 | Phase I | Ipilimumab Ipilimumab + Nivolumab Nivolumab | Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant (CPIT-002) | Active, not recruiting | USA | 0 |
NCT03904069 | Phase I | Anti-FLT3 CAR-T cells | Study Evaluating the Safety, Tolerability, and Efficacy of FLT3 CAR-T AMG 553 in FLT3-positive Relapsed/Refractory AML | Not yet recruiting | USA | 0 |